EPAC2 knockout causes abnormal tau pathology through calpain-mediated CDK5 activation

¹ Department of Pathophysiology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China

² Department of Pathophysiology, School of Basic Medicine, Chongqing Medical University, Chongqing, 400016, China

Advanced Neurology 2022, 1(1), 8 https://doi.org/10.36922/an.v1i1.8

Submitted: 30 November 2021 | Accepted: 22 February 2022 | Published: 16 March 2022

© 2022 by the Authors. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )

Download PDF

Cite

XML

Abstract

Tau pathology, including aberrant tau hyperphosphorylation, aggregation, and mislocalization, is implicated in many neurodegenerative disorders, including Alzheimer’s disease (AD), which is the most prevalent dementia among the elderly. A better understanding of the molecular mechanisms underlying tau pathology should help advance therapies for neurodegenerative diseases. Perturbations in cyclic adenosine monophosphate (cAMP)-dependent signaling play an important role in the pathophysiology of numerous neurological diseases. EPAC2 is an intracellular cAMP receptor whose expression is downregulated in AD. However, the involvement and role of EPAC2 in tau pathology remain unclear. In this study, we report for the 1st time that EPAC2 is downregulated in the hippocampus of Tg2576 mice, a widely used transgenic mouse model of familial AD. Furthermore, genetic deletion of EPAC2 resulted in abnormal hyperphosphorylation at multiple sites on tau. Aberrant tau aggregation and abnormal neuronal morphology were also detected in these EPAC2−/− mice. Administration of inhibitors of CDK5 or calpain effectively rescued the tau pathology in EPAC2−/− mice. This suggests that the activation of CDK5 by calpain plays an important role in the development of tau pathology in these EPAC2−/− mice. Collectively, our findings demonstrate a direct link between EPAC2 and tau pathology, and suggest that the EPAC2 and calpain/CDK5 signaling pathways may have potential as therapeutic targets for AD.

Keywords

CDK5

Tau pathology

EPAC2

Funding

National Natural Science Foundation of China

National Key Research and Development Program of China

Top-Notch Young Talents Program of China

References

[1]

Gong CX, Liu F, Grundke-Iqbal I, Iqbal K, 2005, Post-translational modifications of tau protein in Alzheimer’s disease. J Neural Transm (Vienna), 112(6): 813–838. https://doi.org/10.1007/s00702-004-0221-0

[2]

Mandelkow E, 1999, Alzheimer’s disease. The tangled tale of tau. Nature, 402(6762): 588–589. https://doi.org/10.1038/45095

[3]

Iqbal K, Liu F, Gong CX, 2016, Tau and neurodegenerative disease: The story so far. Nat Rev Neurol, 12(1):15-27. https://doi.org/10.1038/nrneurol.2015.225

[4]

de Rooij J, Zwartkruis FJ, Verheijen MH, et al., (1998) Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature, 396(6710): 474–477. https://doi.org/10.1038/24884

[5]

Zhang CL, Katoh M, Shibasaki T, et al., 2009, The cAMP sensor 2 is a direct tartget of antidiabetic sulfonylurea drugs. Science, 325(5940): 607–610. https://doi.org/10.1126/science.1172256

[6]

Yang Y, Shu X, Liu D, et al., 2012, EPAC null mutation impairs learning and social interactions via aberrant regulation of miR-124 and Zif268 translation. Neuron, 73(4): 774–788. https://doi.org/10.1016/j.neuron.2012.02.003

[7]

Zhou L, Ma SL, Yeung PK, et al., 2016, Anxiety and depression with neurogenesis defects in exchange protein directly activated by cAMP 2-deficient mice are ameliorated by a selective serotonin reuptake inhibitor, Prozac. Transl Psychiatry, 6(9): e881. https://doi.org/10.1038/tp.2016.129

[8]

Mcphee I, Gibson L, Kewney J, et al., 2005, Cyclic nucleotide signalling: A molecular approach to drug discovery for Alzheimer’s disease. Biochem Soc Trans, 33(6): 1330–1332.

[9]

Lee K, 2021, Epac: New emerging cAMP-binding protein. BMB Rep, 54(3): 149–156. https://doi.org/10.5483/BMBRep.2021.54.3.233

[10]

Zhang X, Huang X, Fang C, et al., 2017, miR-124 Regulates the Expression of BACE1 in the Hippocampus Under Chronic Cerebral Hypoperfusion. Mol Neurobiol, 54(4): 2498–24506. https://doi.org/10.1007/s12035-016-9845-y

[11]

Ittner A, Ittner LM, 2018, Dendritic Tau in Alzheimer’s Disease. Neuron, 99(1): 13-27. https://doi.org/10.1016/j.neuron.2018.06.003

[12]

Zaldua N, Gastineau M, Hoshino M, et al., 2007, Epac signaling pathway involves STEF, a guanine nucleotide exchange factor for Rac, to regulate APP processing. FEBS Lett, 581(30): 5814-5818. https://doi.org/10.1016/j.febslet.2007.11.053

[13]

Robichaux WG 3rd, Cheng X, 2018, Intracellular cAMP sensor EPAC: Physiology, pathophysiology, and therapeutics development. Physiol Rev, 98(2): 919-1053. https://doi.org/10.1152/physrev.00025.2017

[14]

Kimura T, Ishiguro K, Hisanaga S, 2014, Physiological and pathological phosphorylation of tau by Cdk5. Front Mol Neurosci, 7: 65. https://doi.org/10.3389/fnmol.2014.00065

[15]

Partrick GN, Zukerberg L, Nikolic, M, et al., 1999, Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature, 402(6762): 615–622. https://doi.org/10.1038/35081149

[16]

Utreras E, Henriquez D, Contreras-Vallejos E, et al., 2013, Cdk5 regulates Rap1 activity. Neurochem Int, 62(6): 848–853. https://doi.org/10.1016/j.neuint.2013.02.011

[17]

Liu J, Yang J, Xu Y, et al., 2017, Roscovitine, a CDK5 inhibitor, alleviates sevoflurane-induced cognitive dysfunction via regulation tau/GSK3beta and ERK/PPARgamma/CREB signaling. Cell Physiol Biochem, 44(2): 423–435. https://doi.org/10.1159/000485008

[18]

Kitagawa S, 2019, Experimental manipulation of calpain activity in vitro. Methods Mol Biol, 1915: 209–218. https://doi.org/10.1007/978-1-4939-8988-1_16

[19]

Fujita H, Kato T, Watanabe N, et al., 2011, Calpain inhibitors stimulate phagocyte functions via activation of human formyl peptide receptors. Arch Biochem Biophys, 513(1): 51–60. https://doi.org/10.1016/j.abb.2011.06.007

[20]

Li K, Liu FF, He CX, et al., 2016, Olfactory deprivation hastens alzheimer-like pathologies in a human tau-overexpressed mouse model via activation of cdk5. Mol Neurobiol, 53(1): 391-401. https://doi.org/10.1007/s12035-014-9007-z

[21]

Greenberg SG, Davies P, 1990, A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. Proc Natl Acad Sci U S A, 87(15): 5827–5831. https://doi.org/10.1073/pnas.87.15.5827

[22]

Wang JZ, Liu F, 2008, Microtubule-associated protein tau in development, degeneration and protection of neurons. Prog Neurobiol, 85(2): 148-175. https://doi.org/10.1016/j.pneurobio.2008.03.002

[23]

Shukla V, Skuntz S, Pant HC, 2012, Deregulated Cdk5 activity is involved in inducing Alzheimer’s disease. Arch Med Res, 43(8): 655–662. https://doi.org/10.1016/j.arcmed.2012.10.015

[24]

Novais F, Starkstein S, 2015, Phenomenology of depression in Alzheimer’s disease. J Alzheimers Dis, 47(4): 845–855. https://doi.org/10.3233/JAD-148004

[25]

Wang X, Wang ZH, Wu YY, et al., 2013, Melatonin attenuates scopolamine-induced memory/synaptic disorder by rescuing EPACs/miR-124/Egr1 pathway. Mol Neurobiol, 47(1): 373-3781. https://doi.org/10.1007/s12035-012-8355-9

[26]

Jones KA, Sumiya M, Woolfrey KM, et al., 2019, Loss of EPAC2 alters dendritic spine morphology and inhibitory synapse density. Mol Cell Neurosci, 98: 19-31. https://doi.org/10.1016/j.mcn.2019.05.001

[27]

Yang X, Yao C, Tian T, et al., 2018, A novel mechanism of memory loss in Alzheimer’s disease mice via the degeneration of entorhinal-CA1 synapses. Mol Psychiatry, 23(2): 199-210. https://doi.org/10.1038/mp.2016.151

[28]

Woolfrey KM, Srivastava DP, Photowala H, et al., 2009, Epac2 induces synapse remodeling and depression and its disease-associated forms alter spines. Nat Neurosci, 12(10): 1275–1284. https://doi.org/10.1038/nn.2386

[29]

Wu M, Zhang M, Yin X, et al., 2021, The role of pathological tau in synaptic dysfunction in Alzheimer’s diseases. Transl Neurodegener. 10(1): 45. https://doi.org/10.1186/s40035-021-00270-1

[30]

Wang Y, Mandelkow E, 2016, Tau in physiology and pathology. Nat Rev Neurosci, 17(1): 5-21. https://doi.org/10.1038/nrn.2015.1

[31]

Fulga TA, Elson-Schwab I, Khurana V, et al., 2007, Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo. Nat Cell Biol, 9(2): 139–148. https://doi.org/10.1038/ncb1528

[32]

Jadhav S, Cubinkova V, Zimova I, et al., 2015, Tau-mediated synaptic damage in Alzheimer’s disease. Transl Neurosci, 6(1): 214–226. https://doi.org/10.1515/tnsci-2015-0023

[33]

Wang JZ, Grundke-Iqbal I, Iqbal K, 2007, Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur J Neurosci, 25(1): 59-68. https://doi.org/10.1111/j.1460-9568.2006.05226.x

[34]

Götz J, Nitsch RM, 2001, Compartmentalized tau hyperphosphorylation and increased levels of kinases in transgenic mice. Neuroreport, 12(9): 2007–2016. https://doi.org/10.1097/00001756-200107030-00045

[35]

Liu T, Perry G, Chan HW, et al., 2004, Amyloid-beta-induced toxicity of primary neurons is dependent upon differentiation-associated increases in tau and cyclin-dependent kinase 5 expression. J Neurochem, 88(3): 554–563. https://doi.org/10.1046/j.1471-4159.2003.02196.x

[36]

Castro-Alvarez JF, Uribe-Arias SA, Mejia-Raigosa D, et al., 2014, Cyclin-dependent kinase 5, a node protein in diminished tauopathy: A systems biology approach. Front Aging Neurosci, 6: 232. https://doi.org/10.3389/fnagi.2014.00232

[37]

Lopes JP, Oliveira CR, Agostinho P, 2010, Neurodegeneration in an Abeta-induced model of Alzheimer’s disease: The role of Cdk5. Aging Cell, 9(1): 64-77. https://doi.org/10.1111/j.1474-9726.2009.00536.x

[38]

Lee MS, Kwon YT, Li M, et al., 2000, Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature, 405(6784): 360–364. https://doi.org/10.1038/35012636

[39]

Liu F, Su Y, Li B, et al., 2003, Regulation of amyloid precursor protein (APP) phosphorylation and processing by p35/Cdk5 and p25/Cdk5. FEBS Lett, 547(1-3): 193-196. https://doi.org/10.1016/s0014-5793(03)00714-2

[40]

Joshi G, Bekier ME 2nd, Wang Y, 2015, Golgi fragmentation in Alzheimer’s disease. Front Neurosci, 9: 340. https://doi.org/10.3389/fnins.2015.00340

[41]

McBrayer M, Nixon RA, 2013, Lysosome and calcium dysregulation in Alzheimer’s disease: partners in crime. Biochem Soc Trans, 41(6): 1495–1502. https://doi.org/10.1042/BST20130201

[42]

Ferreira A, 2012, Calpain dysregulation in Alzheimer’s disease. ISRN Biochem, 2012: 728571. https://doi.org/10.5402/2012/728571

[43]

Camins A, Verdaguer E, Folch J, et al., 2006, involvement of calpain activation in neurodegenerative processes. CNS Drug Rev, 12(2): 135–148. https://doi.org/10.1111/j.1527-3458.2006.00135.x

[44]

Jeronimo-Santos A, Vaz SH, Parreira S, et al., 2015, Dysregulation of TrkB receptors and BDNF function by amyloid-beta peptide is mediated by calpain. Cereb Cortex, 25(9): 3107–3121. https://doi.org/10.1093/cercor/bhu105

[45]

Liang B, Duan BY, Zhou XP, et al., 2010, Calpain activation promotes BACE1 expression, amyloid precursor protein processing, and amyloid plaque formation in a transgenic mouse model of Alzheimer disease. J Biol Chem, 285(36): 27737–2744. https://doi.org/10.1074/jbc.M110.117960

[46]

Park SY, Ferreira A, 2005, The generation of a 17 kDa neurotoxic fragment: an alternative mechanism by which tau mediates beta-amyloid-induced neurodegeneration. J Neurosci, 25(22): 5365–5375. https://doi.org/10.1523/JNEUROSCI.1125-05.2005

Conflict of interest

The authors have no conflicts of interest to declare.

Previous article in this issue

Next article in this issue

Advanced Neurology, Electronic ISSN: 2810-9619 Published by AccScience Publishing